V600e - Cancer Science

Relevant Publications

A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma.

Issue Release: 2024

Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution.

Issue Release: 2024

Targeting the RAS upstream and downstream signaling pathway for Cancer treatment.

Issue Release: 2024

Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.

Issue Release: 2024

Complete response of metastatic microsatellite-stable V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.

Issue Release: 2024

MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.

Issue Release: 2024

Universal Lynch Syndrome Screening in Colorectal Cancer: A 5-Year Experience of a Portuguese Pathology Department.

Issue Release: 2024

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.

Issue Release: 2024

Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study.

Issue Release: 2024

Current status of precision oncology in adult glioblastoma.

Issue Release: 2024

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

Issue Release: 2024

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.

Issue Release: 2024

Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.

Issue Release: 2024

[Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].

Issue Release: 2024

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

Issue Release: 2024

Pathologic characteristics of histiocytic and dendritic cell neoplasms.

Issue Release: 2024

Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma.

Issue Release: 2024

Acoustic detection of a mutation-specific Ligase Chain Reaction based on liposome amplification.

Issue Release: 2024

BRAF V600E in a preclinical model of pleomorphic Xanthoastrocytoma: Analysis of the tumor microenvironment and immune cell infiltration dynamics .

Issue Release: 2024

Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic V600EMT colon cancer patient with acquired amplification and fusion: a case report.

Issue Release: 2024

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Partnered Content Networks

Relevant Topics